Objectives To investigate the expression of integrinβ5(ITGB5)in gastric adenocarcinoma(GC) for assessing the correlation between ITGB5 and clinical pathological characteristics,and identifying therapeutic targets for diagnosis and treatment of gastric adenocarcinoma. Methods Levels of ITGB5 were detected in 101 cases of GC tissues and 72 cases of corresponding adjacent non-neoplastic tissues by using tissue microarray and immunohistochemistry(IHC)technique. Then,the correlation between expression of ITGB5 and clinicopathological features as well as prognosis of GC patients was evaluated. Results The expressions of ITGB5 in gastric adenocarcinoma tissues were significantly lower than adjacent non-neoplastic tissues(overexpression rate is 50.5% and 94.4%,respectively,χ2=37.82,P<0.001). The low expression of ITGB5 was related to low differentiation of the tissues、tumor node metastasis classification and clinical stage. Cox regression analysis indicated that low expression of ITGB5 was significantly related to lower survival,and both Kaplan Meier survival and Cox regression analysis showed that low ITGB5 expression(HR=1.95, 95%CI 1.08 to 3.51,P=0.026)was an independent prognosis factor. Conclusions ITGB5 is closely related to the occurrence and progression of GC patients,suggesting that it may be a potential therapeutic target and prognosis index in GC.%目的 检测整合素β5(ITGB5)在胃癌中的表达情况,探讨其与胃癌发生发展的关系,以寻找胃癌新的诊断和治疗靶点.方法 采用组织芯片技术构建包含101例胃癌组织和72例配对的癌旁组织共173点阵石蜡组织芯片,用免疫组化法检测该芯片中整合素β5的表达,分析其与胃癌临床病理及预后的关系.结果 整合素β5在胃癌组织和癌旁组织高表达率分别为50.5%(51/101)和94.4%(68/72),差异有统计学意义(χ2=37.82,P<0.001),低表达的整合素β5与肿瘤分化程度、淋巴结转移和临床分期有关(P<0.05),单因素分析显示低表达组的生存率比高表达组低,差异有统计学意义(P=0.003),并且COX风险模型中提示整合素β5是胃癌预后的独立危险因素(P=0.026).结论 整合素β5的低表达与胃癌发生发展有密切关系,可能是新的治疗靶点或预后评估指标.
展开▼
